Loading company…
Sonas Pharma develops cannabinoid therapies for neurological and metabolic conditions.
Sonas Pharma develops cannabinoid therapies focused on epilepsy and obesity, using molecular engineering and formulation strategies. The company is based in Belfast, UK, and is working toward early-stage laboratory capabilities. In February 2026, it raised an undisclosed amount of pre-seed funding led by SFC Capital, with participation from Clarendon Fund Managers.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in